Anzeige
Mehr »
Login
Montag, 29.11.2021 Börsentäglich über 12.000 News von 683 internationalen Medien
Rücksetzer eröffnet geniale Kaufchance bei ETHEREUM! Gebührenfreier ETN von Valour macht Spaß!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881535 ISIN: US75886F1075 Ticker-Symbol: RGO 
Tradegate
26.11.21
21:47 Uhr
570,00 Euro
+2,10
+0,37 %
1-Jahres-Chart
REGENERON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
REGENERON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
570,70572,0026.11.
565,90569,8026.11.

Aktuelle News zur REGENERON PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoRegeneron signs $900m cancer and infectious disease deal with Nykode7
REGENERON PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiVaccibody AS: Nykode Therapeutics resolves to issue shares to Regeneron8
MiChasing Regeneron, Pfizer posts data on $250M cardiovascular bet14
DiVaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus5
DiNykode Therapeutics partners with Regeneron to develop cancer and infectious disease vaccines2
DiVaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron3
DiVaccibody becomes Nykode Therapeutics, teams up with Regeneron on cancer vaccines3
DiNykode Inks Multi-mln Dollar Deal With Regeneron To Develop Cancer, Infectious Diseases Vaccines186WASHINGTON (dpa-AFX) - Nykode Therapeutics (VACC), a developer of vaccines and novel immunotherapies, said on Tuesday that it has signed a license and collaboration deal with a potential of...
► Artikel lesen
DiVaccibody AS: Nykode Therapeutics enters into multi-target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases7
DiNykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases203Multi-target agreement covers five programs focused on off-the-shelf vaccines for cancer and infectious disease Nykode Therapeutics (formerly Vaccibody) to receive an upfront payment of...
► Artikel lesen
22.11.Regeneron Extends Hearing Loss Gene Therapy pact With Decibel3
22.11.Decibel up 4% on research extension with Regeneron for hearing loss therapies3
22.11.Decibel Therapeutics, Inc.: Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop ...1
20.11.Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much7
17.11.Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More3
17.11.Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders1
15.11.Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail20
15.11.Regeneron's COVID-19 antibody cocktail approved in Europe14
13.11.EU Approves Regeneron Antibody Cocktail To Treat And Prevent COVID-191.323WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) said Friday that European Commission has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV in the U.S....
► Artikel lesen
12.11.Regeneron announces $3 billion share buyback program11
Seite:  Weiter >>
375 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
28,2,4